Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

After years of preparation, Eli Lilly is on the brink of launching ... The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

Two years ago, Eli Lilly started working with Dexcom ... app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the basis of the drugmaker’s ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

The insulins available without a prescription come in vials and pens that may need ... you’re looking to use OTC insulin, you may also want to consider Eli Lilly’s affordable options, which ...

These drugs work by stimulating insulin secretion to lower blood sugar ... In August 2024, the shortage ended when Eli Lilly introduced tirzepatide as Zepbound. Patients with electronic ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...